peginesatide (Omontys)

^[1]^[2]

Indications

> 10%
- arthralgia, diarrhea, hypertension, vomiting
- higher risk of cardiovascular events (RR = 1.32) & mortality than darbepoetin in patients with chronic renal failure NOT on dialysis^[2]
- adverse effects similar to epoietin-alpha in patients on dialysis^[2]

↑ FDA NEWS RELEASE: March 27, 2012 FDA approves Omontys to treat anemia in adult patients on dialysis http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm297464.htm
↑ ^2.0 ^2.1 ^2.2 ^2.3 Fishbane S et al Peginesatide in Patients with Anemia Undergoing Hemodialysis. N Engl J Med 2013; 368:307-319January 24, 2013 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/23343061 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMoa1203165
Macdougall IC et al Peginesatide for Anemia in Patients with Chronic Kidney Disease Not Receiving Dialysis. N Engl J Med 2013; 368:320-332January 24, 2013 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/23343062 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMoa1203166
Drueke TB Anemia Treatment in Patients with Chronic Kidney Disease. N Engl J Med 2013; 368:387-389January 24, 2013 PMID: https://www.ncbi.nlm.nih.gov/pubmed/23343068 p://www.nejm.org/doi/full/10.1056/NEJMe1215043